- Residency - UT Southwestern Medical Center (1997-2000), Internal Medicine
- Fellowship - University of California at San Diego School of Medicine (2002-2005), Pulmonary Diseases & Critical Care Medicine
- Medical School - UT Southwestern Medical School (1992-1996)
Kelly Chin, M.D.
- Internal Medicine - Pulmonary Disease
- Lung (Pulmonary) Disorders
- Pulmonary Hypertension
Kelly Chin, M.D., is an Assistant Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center. She specializes in treatment and research of pulmonary hypertension.
Dr. Chin attended UT Southwestern for her medical degree and her residency in internal medicine. She went to the University of California, San Diego, for a fellowship in pulmonary, critical care, and pulmonary hypertension. She joined the UT Southwestern faculty in 2005.
She conducts clinical research into pulmonary hypertension treatments, markers of prognosis, and risk factors for pulmonary hypertension, such as methamphetamine use.
Dr. Chin is board certified in internal medicine, pulmonary disease, and critical care medicine by the American Board of Internal Medicine.
She was named a Super Doctor by Texas Monthly in 2018.
Meet Dr. Chin
Pulmonary Hypertension Specialist
When pulmonologist Kelly Chin, M.D., started treating patients with pulmonary hypertension, it was a newly treatable disease – only six years before, there were no effective treatment options for most people with the disease.
"We offer access to the best treatments for pulmonary hypertension."
Since then, she's witnessed multiple advances in treatment options for patients who suffer from this often fatal disease. The opportunity for her patients to live a better life motivates her.
"After we've started them on therapy, we can see patients get better and really respond in a positive way,” she says. “It's very rewarding as a physician to impact someone's life in that way."
As Director of UT Southwestern Medical Center's Pulmonary Hypertension Program, Dr. Chin has also seen the Program grow quickly. It now ranks among the largest centers in the country, providing access to state-of-the-art treatments.
In addition to clinical care, Dr. Chin spends time researching causes and new treatments for pulmonary hypertension. While experts have identified some risk factors for the disease such as medication exposures and certain genes, there is a need to learn more. Dr. Chin is exploring other potential causes, such as a possible connection between stimulant use and pulmonary hypertension.
Dr. Chin loves seeing the impact new therapies can have on her patients. A pulmonary hypertension diagnosis no longer means a patient is going to die within a few years, she says.
"While it’s still a serious condition, many people improve and feel a lot better,” Dr. Chin notes. “It's certainly treatable. Patients can achieve a significant improvement in quality-of-life with medication. "
- Pulmonary Hypertension Association
- American Thoracic Society
- American Medical Association
- American College of Chest Physicians
- College of Natural Science Dean’s Honor List 1989-1992 1990
- Southwestern Medical Foundation Medical School Scholarship 1992-1996 1992
- College of Natural Sciences College Scholar Award 1992
- Finalist, Alfred Soffer Research Award 2007, ACCP Original Research Award
Pulmonary Hypertension in Murray and Nadel's Textbook of Respiratory Medicine
Chin KM, Channick RN. (2015)
Chronic Thromboembolic Pulmonary Hypertension in Pulmonary Vascular Disease
Chin K, Fedullo P. (2006)
Surgical Treatments in Pulmonary Hypertension. A Patient's Survival Guide
Chin KM, Torres F (2011)
- Pulmonary Hypertension in Murray and Nadel's Textbook of Respiratory Medicine
Characterizing the right ventricle: advancing our knowledge.
Chin KM, Coghlan G The American journal of cardiology 2012 Sep 110 6 Suppl S3-8
Pulmonary Hypertension: Diagnosis and Treatment
Chin, KM, Channick RN, Rubin LJ Manual of Clinical Problems in Pulmonary Medicine 2004
Surgical Treatments for Pulmonary Hypertension.
Chin KM, Torres F In Pulmonary Hypertension. A Patient?s Survival Guide. RJ Oudiz, MD, ed. 2011
Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
Chin KM, Channick RN, Kim NH, Rubin LJ Chest 2007 Sep 132 3 786-92
Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ Chest 2009 Jan 135 1 130-6
Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: A Systematic Review and Meta-Analysis.
Pandey A, Garg S, Khunger M, Garg S, Kumbhani DJ, Chin KM, Berry JD Circulation. Heart failure 2015 Jul
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV The New England journal of medicine 2015 Dec 373 26 2522-33
Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials.
Chin KM, Bartolome S, Miller K, Blair C, Gillies H, Torres F International journal of clinical practice 2014 Feb
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM Journal of the American College of Cardiology 2013 Dec 62 25 Suppl D22-33
International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies.
Link J, Glazer C, Torres F, Chin K Chest 2011 Mar 139 3 497-504
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
Blalock SE, Matulevicius S, Mitchell LC, Reimold S, Warner J, Peshock R, Torres F, Chin KM Journal of cardiac failure 2010 Feb 16 2 121-7
Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
Chin KM, Kingman M, de Lemos JA, Warner JJ, Reimold S, Peshock R, Torres F The American journal of cardiology 2008 Jun 101 11 1669-72
Pulmonary arterial hypertension.
Chin KM, Rubin LJ Journal of the American College of Cardiology 2008 Apr 51 16 1527-38
The right ventricle in pulmonary hypertension.
Chin KM, Kim NH, Rubin LJ Coronary artery disease 2005 Feb 16 1 13-8
Chin K, Channick R Expert Rev Cardiovasc Ther. 2004 2(2) 175-82
Association of Cardiac Troponin I With Disease Severity and Outcomes in Patients With Pulmonary Hypertension.
Vélez-Martínez M, Ayers C, Mishkin JD, Bartolome SB, García CK, Torres F, Drazner MH, de Lemos JA, Turer AT, Chin KM The American journal of cardiology 2013 Mar
Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
Chin KM, Channick RN, Rubin LJ Chest 2006 Dec 130 6 1657-63
Idiopathic and Heritable Pulmonary Hypertension: Introduction to Pathophysiology and Clinical Aspects.
Chin KM, Torres F, Rubin LJ In Pulmonary Circulation. LJ Rubin, AJ Peacock, eds. 2011
Chronic Thromboembolic Pulmonary Hypertension
Chin KM, Fedullo P Pulmonary Vascular Disease 2006 Mandel J, Taichman D, eds
Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension.
Darsaklis K, Dickson ME, Cornwell W, Ayers CR, Torres F, Chin KM, Matulevicius S The international journal of cardiovascular imaging 2016 Apr
Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center.
Chin KM, Ruggiero R, Bartolome S, Velez-Martinez M, Darsaklis K, Kingman M, Harden S, Torres F Pulmonary circulation 2015 Sep 5 3 513-20
Left atrial structure and function and clinical outcomes in the general population.
Gupta S, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, de Lemos JA, Peshock RM, Drazner MH European heart journal 2012 Jul
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA, Chin KM Drug design, development and therapy 2016 10 3747-3754
Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V American heart journal 2014 Feb 167 2 218-225.e1
Telomere shortening in familial and sporadic pulmonary fibrosis.
Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK American journal of respiratory and critical care medicine 2008 Oct 178 7 729-37
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N European journal of heart failure 2019 Jan
"Treat-to-close": Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry.
Bradley EA, Ammash N, Martinez SC, Chin K, Hebson C, Singh HS, Aboulhosn J, Grewal J, Billadello J, Chakinala MM, Daniels CJ, Zaidi AN, International journal of cardiology 2019 Sep 291 127-133
Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.
Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R The European respiratory journal 2019 Jan 53 1
Differentiating Precapillary From Postcapillary Pulmonary Hypertension.
Naeije R, Chin K, Circulation 2019 Aug 140 9 712-714
Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study.
Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galié N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Circulation 2019 Apr
Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical Centers.
Furfaro D, Azadi J, Housten T, Kolb TM, Damico RL, Hassoun PM, Chin K, Mathai SC, Annals of the American Thoracic Society 2019 Feb 16 2 277-280
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2019 Jan 38 1 43-50
- Characterizing the right ventricle: advancing our knowledge.
- Pulmonary Hypertension
- Lung (Pulmonary) Disorders
- Pulmonary Hypertension